DeVita Vt
About
In The Last Decade
DeVita Vt
51 papers receiving 1.0k citations
Hit Papers
Peers
Comparison fields: 5 of 96
- Surgery 475
- Pathology and Forensic Medicine 348
- Oncology 323
- Reproductive Medicine 315
- Pulmonary and Respiratory Medicine 199
Countries citing papers authored by DeVita Vt
This map shows the geographic impact of DeVita Vt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by DeVita Vt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites DeVita Vt more than expected).
Fields of papers citing papers by DeVita Vt
This network shows the impact of papers produced by DeVita Vt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by DeVita Vt. The network helps show where DeVita Vt may publish in the future.
Co-authorship network of co-authors of DeVita Vt
This figure shows the co-authorship network connecting the top 25 collaborators of DeVita Vt. A scholar is included among the top collaborators of DeVita Vt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with DeVita Vt. DeVita Vt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | The cell cycle: Probing new molecular determinants of resistance and sensitivity to cytotoxic agents. | 2 |
| 2 | The use of combination chemotherapy in the treatment of early stage Hodgkin's disease. | 8 |
| 3 | Is a mechanism such as the NCI's Clinical Alert ever an appropriate alternative to journal peer review? | 2 |
| 4 | NCI's breast cancer clinical alert: rationale and results. | 0 |
| 5 | The evolution of chemotherapy of lymphomas of adults. | 8 |
| 6 | Hematologic malignancies: non-Hodgkin's lymphomas. | 1 |
| 7 | What are clinical trials all about? | 2 |
| 8 | Contrasting viewpoints on cancer drug development: the Wooldridge and Richardson reports. | 1 |
| 9 | Advances in cancer therapeutics: chemotherapy. | 1 |
| 10 | Clinical characteristics of Pneumocystis carinii pneumonia. | 4 |
| 11 | The dilemma regarding postoperative chemotherapy in primary carcinoma of the colon. | 8 |
| 12 | Future prospectives in the treatment of breast cancer. | 3 |
| 13 | Sequential staging in non-Hodgkin's lymphoma. | 34 |
| 14 | Proceedings of the Conference on non-Hodgkin's lymphomas: summary of symposium. | 3 |
| 15 | Reversible penile calcifications associated with bleomycin (NSC-125066)-induced pulmonary toxicity. | 4 |
| 16 | High-dose intermittent intravenous infusion of procarbazine (NSC-77213). | 7 |
| 17 | Intensive chemotherapy for Hodgkin's disease: long-term complications. | 25 |
| 18 | Combined drug treatment of Hodgkin's disease: remission induction, remission duration, and survival; an appraisal. | 9 |
| 19 | Effects of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) and its degradation products on progression of L1210 cells through the cell cycle. | 8 |
| 20 | SOME PHARMACOLOGIC PROPERTIES OF A NEW ANTITUMOR AGENT, N-ISOPROPYL-ALPHA-(2-METHYLHYDRAZINO)-P-TOLUAMIDE, HYDROCHLORIDE (NSC-77213). | 20 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.